Uncertainty Over BRCA Testing Reimbursement Remains
This article was originally published in The Gray Sheet
Executive Summary
In recently updated clinical lab fee schedule rates, Medicare payment for BRCA1 and BRCA2 genetic testing goes down from $2,795 to $1,438, but Myriad Genetics believes the change might be a clerical error, repeating an issue from September.
You may also be interested in...
MolDx Labs Question Missing Medicare Payment Amounts For Some Test Codes
Clinical laboratories plan to talk to CMS about its decision to list only 65 out of 114 new molecular pathology codes when it released revised gap-fill pricing Sept. 30, as well as concerns about perceived changes to the gap-fill regulation.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.